Hydrogel Matrix for Localized Inflammation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic wounds fail to effectively address the prolonged inflammatory phase and the failure to initiate the proliferative phase of healing, leading to incomplete closure and increased infection risk.
Innovation Solution
A composition comprising a hydrophilic polymer with covalently attached cytokine-neutralizing antibodies and a cellular adhesion peptide, which localizes the inflammatory response and promotes cellular migration and attachment, thereby inhibiting the inflammatory response and initiating tissue regeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If current treatments are applied to chronic wounds, then the inflammatory phase is suppressed, but the proliferative phase is not initiated and wound closure remains incomplete
Solution Approach 1:
The patent uses a hydrogel matrix as an intermediary carrier that delivers both anti-inflammatory agents (to suppress the prolonged inflammatory phase) and growth factors (to initiate the proliferative phase). This intermediary system enables coordinated delivery of multiple therapeutic agents that work synergistically to resolve the contradiction between suppressing inflammation and promoting wound closure.
Solution Approach 2:
The invention employs a composite hydrogel formulation containing multiple bioactive components including anti-inflammatory cytokines, growth factors, and extracellular matrix mimetics. This composite material simultaneously addresses the prolonged inflammatory phase and the failure to initiate proliferation, resolving the contradiction by integrating multiple therapeutic functions into a single treatment system.
2Object-affected harmful factors
If anti-inflammatory agents are applied to chronic wounds, then inflammation is reduced, but tissue regeneration is not enhanced
Solution Approach 1:
The patent merges anti-inflammatory therapy with pro-regenerative therapy by formulating a single hydrogel composition that contains both anti-inflammatory agents (such as IL-10 or TGF-β) and growth-promoting factors (such as VEGF, FGF, or PDGF). This combination approach ensures that inflammation is reduced while tissue regeneration is simultaneously enhanced, resolving the contradiction between these two therapeutic goals.
Solution Approach 2:
The hydrogel matrix provides continuous localized delivery of both anti-inflammatory and pro-regenerative agents over an extended period. This continuous action ensures sustained suppression of inflammation while simultaneously maintaining stimulation of tissue regeneration, preventing the contradiction from recurring during the healing process.
Data Source
AI summary
The various embodiments provide a composition that provides local control over inflammation. The composition localizes the activities of the cytokine-neutralizing antibodies to the site of inflammation through covalent attachment to hydrophilic matrices. The various embodiments including a hydrophilic polymer, a ligand binding moiety covalently attached to the polymer, and optionally, a cellular adhesion peptide covalently attached to the polymer. The hydrophilic polymer may be a glycosaminoglycan such as hyaluronan. The cellular adhesion peptide may be a linear RGD peptide sequence covalently attached to the polymer. The ligand binding moiety may be a monoclonal antibody covalently attached to the polymer. The antibody may be selected from the group consisting of an anti-IL-1β, an anti-IL-6, an anti-TNF-α, and combinations thereof. The polymer functions as a substrate or matrix for cell migration and tissue regeneration. The RGD peptide functions to promote cellular proliferation, migration and attachment to the polymer. The monoclonal antibody functions to inhibit the inflammatory response.